ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
businesswire.com
news
2022-10-20 00:00:00

October 20, 2022 04:01 PM Eastern Daylight Time WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its third quarter 2022 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, please register here.
